Intermittent claudication: Symptom severity versus health values

Intermittent claudication as the presenting symptom in primary amyloidosis.

Intermittent claudication: how should we react to this symptom?

Management (AFFIRM) trial, which may shed indirect light on the merit of use of amiodarone on the grounds of its superior efficacy. On the other hand, a longer duration of follow-up would allow sufficient time for development of amiodarone organ toxicity with its attendant significant costs. The major adverse effects of sotalol and propafenone are predominantly seen early in the treatment cours...

Intermittent claudication

Peripheral arterial disease is a common health problem that globally affects over 200 million individuals, and intermittent claudication (IC) is the most common symptomatic presentation. The leg symptoms in IC are provoked by walking exercise and can be alleviated by medical intervention, exercise training and invasive vascular interventions (revascularization). The quality of evidence for inva...

Patients with Intermittent Claudication

Increased blood viscosity has been shown to be an important factor in reducing blood flow in a review and analysis of the history, clinical findings, and haemodynamic, rheological, radiological, and biochemical measurements in 126 patients with intermittent claudication. In some patients increased viscosity seemed to be the determining cause of claudication. A raised plasma fibrinogen was the m...

Intermittent claudication: cost-effectiveness of revascularization versus exercise therapy.

PURPOSE To compare the costs, effectiveness, and cost-effectiveness of alternative treatment strategies for intermittent claudication. MATERIALS AND METHODS By combining data from the literature and original patient data, a Markov decision model was developed to evaluate the societal cost-effectiveness. Patients presented with previously untreated intermittent claudication, and treatment opti...